Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05460507 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Name: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment — clinical trial record (NCT05460507)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorCerenome

Started2024-12-12

View on ClinicalTrials.gov ↗

Amendment history

2025-03-25

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-03-01→confirmed 2024-12-12

Study sites0→1

2024-07-24

Study Status, Contacts/Locations v3

Primary completion date2025-01-31→2028-03-01

Completion date2025-01-31→2028-03-01

Start date2023-01-02→2025-03-01

2022-12-22

Study Status v2

Start date2022-12-10→2023-01-02

2022-12-07

Study Status, Contacts/Locations v1

Start date2022-08-30→2022-12-10

2022-07-12

Original filing

Cerenome

5 trials monitored

See 1 trial at risk

Glioma

666 trials monitored

See 38 trials at risk

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

Trial Details

NCT Number	NCT05460507
Lead Sponsor	Cerenome
Conditions	Glioma
Enrollment	40 participants
Start Date	2024-12-12
Primary Completion	2028-03-01 (estimated)
Study Completion	2028-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-30